Trials / Unknown
UnknownNCT02869984
Clinical Trial Assessing 5-HT3 Receptor Antagonist (Ramosetron) for the Treatment of Anterior Resection Syndrome
- Status
- Unknown
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- Seoul National University Hospital · Academic / Other
- Sex
- Male
- Age
- 19 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Poor functional outcomes has been reported inevitably, and up to 90% of the patients have experienced bowel habit changes after sphincter-saving surgery for rectal cancer. But, currently there has been no specific treatment for ARS and symptom based empirical management is tried Recently, 5-HT3 receptor antagonists can be used for treatment of IBS-D, and has been revealed to be slowing the bowel movement and improving stool consistency and urgency. We performed the clinical trial with using ramosetron (Irribow®) for the treatment of ARS
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ramosetron |
Timeline
- Start date
- 2016-08-01
- Primary completion
- 2018-10-01
- First posted
- 2016-08-17
- Last updated
- 2016-08-17
Source: ClinicalTrials.gov record NCT02869984. Inclusion in this directory is not an endorsement.